Galliprant vs Meloxicam, Carprofen, Rimadyl, Gabapentin & Librela

Canine osteoarthritis (OA) affects approximately 20% of dogs over one year of age in North America, making it one of the most commonly treated conditions in veterinary medicine. The number of available medications has expanded significantly in recent years — from traditional NSAIDs like meloxicam and carprofen to the newer EP4-targeting Galliprant, the injectable Librela (monoclonal antibody), and adjunct therapies like gabapentin. Understanding the real differences between these options helps you have a more productive conversation with your veterinarian. Here are the 10 most important facts every dog owner should know.

• 1
  What is Galliprant and how is it different from meloxicam and carprofen? Galliprant (grapiprant) = first FDA-approved piprant-class drug for dogs · Blocks only the EP4 prostaglandin receptor — the specific pain pathway for osteoarthritis · Meloxicam and carprofen are traditional NSAIDs — they block COX enzymes, suppressing all prostaglandins including protective ones · Result: Galliprant is more targeted with potentially fewer GI, kidney, and liver effects than traditional NSAIDs

  Galliprant’s active ingredient, grapiprant, works through a completely different mechanism than any traditional NSAID. Classic pain medications for dogs — including meloxicam (Metacam), carprofen (Rimadyl, Novox), firocoxib (Previcox), and deracoxib (Deramaxx) — all work by inhibiting COX enzymes (cyclooxygenase-1 and/or cyclooxygenase-2), which reduces the production of prostaglandins across the board. This is effective for pain, but prostaglandins also perform critical protective functions: maintaining the stomach’s protective lining, regulating kidney blood flow, and supporting normal platelet function. Blocking them non-selectively creates the risk of gastrointestinal ulceration, kidney injury, and liver stress. Galliprant takes a fundamentally different approach: rather than blocking prostaglandin production, it blocks only the EP4 receptor — the specific docking site where prostaglandin E2 (PGE2) triggers osteoarthritis pain and inflammation. Other prostaglandin receptors and their protective functions remain undisturbed. Think of traditional NSAIDs as shutting down an entire factory, while Galliprant disconnects only the specific alarm wire causing the pain signal. This targeted mechanism is why Galliprant is described as having a cleaner safety profile for long-term use in dogs with sensitive stomachs, early-stage kidney issues, or organ sensitivities that make traditional NSAIDs risky.
• 2
  Is Galliprant better than meloxicam for dogs? For pure osteoarthritis pain: clinically equivalent — a 2024 randomized, double-blinded clinical trial (JVIM / NIH/PMC) found no statistically significant difference in pain scores between grapiprant and meloxicam over 14 days · For GI tolerance and long-term organ safety: Galliprant has the advantage, especially for senior dogs and those with mild pre-existing organ disease · For broader pain conditions (post-surgical, acute injury): meloxicam may be more potent

  A landmark 2024 randomized, double-blinded, prospective clinical trial published in the Journal of Veterinary Internal Medicine (Cassemiche et al., PMC11256200) directly compared grapiprant (Galliprant) against meloxicam in 48 dogs recovering from tibial plateau leveling osteotomy (TPLO) knee surgery. Dogs were assessed using the validated Canine Brief Pain Inventory (CBPI) at days 3, 7, 10, and 15 post-surgery. The study found no statistically significant difference in pain severity or pain interference scores between the two treatments across all evaluation time points. In plain terms: for controlling acute post-surgical joint pain in dogs, Galliprant and meloxicam performed equally well. This mirrors the non-inferiority findings from Galliprant’s original FDA registration studies. However, the clinical picture is more nuanced. Meloxicam, by inhibiting COX enzymes more broadly, may provide more potent anti-inflammatory effects in conditions involving systemic inflammation beyond pure osteoarthritis. Galliprant, by contrast, shines for the chronic low-grade osteoarthritis pain that most aging dogs live with — and its more favorable organ safety profile makes it a better long-term choice for dogs whose kidneys, liver, or stomach cannot tolerate traditional NSAIDs. Neither drug is universally “better” — the right choice depends on your individual dog’s condition, health profile, and tolerance history.
• 3
  Galliprant vs Rimadyl (carprofen) — which is safer for senior dogs? Galliprant: safer for long-term use in senior dogs, especially those with sensitive stomachs, mild kidney disease, or prior NSAID intolerances · Rimadyl (carprofen): faster-acting for acute pain; FDA-approved from 6 weeks of age; available in chewable tablet form; better for short-term or post-surgical pain · Both require baseline bloodwork and periodic monitoring · Neither should be combined with the other or with steroids

  Rimadyl (carprofen), manufactured by Zoetis, has been a cornerstone of veterinary pain management for over 25 years — and for good reason. It is highly effective, fast-acting (dogs can feel relief within 2 hours), and available in palatable chewable tablets that make dosing easy. Carprofen selectively inhibits COX-2 while having less effect on COX-1 than older non-selective NSAIDs, reducing (but not eliminating) the risk of gastrointestinal side effects. For healthy, active dogs needing short-term pain control, Rimadyl remains an excellent option. For senior dogs requiring chronic daily pain management — particularly those with any degree of reduced kidney function, elevated liver enzymes, or a history of GI problems on other NSAIDs — Galliprant offers a meaningfully more favorable safety profile. Because Galliprant bypasses COX inhibition entirely, it spares the protective prostaglandins that maintain gastric mucosa integrity and renal blood flow. In dogs where repeated bloodwork has shown rising kidney values on carprofen, many veterinarians switch to Galliprant as a safer long-term alternative. One practical advantage of carprofen: it is available as a generic (Novox, Vetprofen, and others) at significantly lower cost, and it has broader indications including fever management and non-OA pain that Galliprant does not cover. The FDA label for Rimadyl has a lower minimum age (6 weeks) compared to Galliprant’s 9-month minimum.
• 4
  Can you give a dog Galliprant and gabapentin together? Yes — Galliprant and gabapentin are frequently combined in veterinary practice for multimodal pain management · They target different pain pathways: Galliprant addresses inflammatory joint pain (EP4 receptor); gabapentin addresses neuropathic/nerve pain · Combining the two (“the two G’s”) is a common strategy for dogs with moderate-to-severe OA or when one drug alone becomes insufficient · Always under veterinary supervision — dosing and monitoring are required for both

  Combining Galliprant and gabapentin is one of the most common multimodal pain management strategies in veterinary medicine for dogs with advancing osteoarthritis. Gabapentin (also marketed as Neurontin) is an anticonvulsant drug that reduces pain by blocking neuropathic (nerve) pain pathways — specifically, it modulates calcium channels in the nervous system that transmit pain signals. This mechanism is entirely separate from Galliprant’s EP4 receptor blockade. When osteoarthritis advances, dogs often experience both inflammatory joint pain (which Galliprant addresses) and neuropathic pain from nerve sensitization (which gabapentin addresses). The two drugs are not NSAIDs and do not interact through the same pathway — making them genuinely complementary rather than redundant. In clinical practice and owner reports, this combination is sometimes called “the two G’s” and is a recognized progression step when Galliprant alone is no longer providing adequate relief. Gabapentin’s most common side effects in dogs are mild sedation and mild ataxia (wobbly gait), particularly at higher doses. These are dose-dependent and often resolve after the first week of use. Unlike Galliprant, gabapentin does not require baseline organ bloodwork — though periodic checks remain good practice for any dog on long-term medication. Important: combining gabapentin and Galliprant is a decision to make with your veterinarian, who will determine appropriate doses for your dog’s weight and severity of disease.
• 5
  What are the side effects of Galliprant in dogs? Most common: vomiting, diarrhea, soft or mucoid stools, decreased appetite, mild lethargy · Rare post-approval reports (FDA AAHA update): GI bleeding, renal and hepatic bloodwork changes, weight loss, panting, ataxia · FDA updated the safety label post-approval to add these warnings and require that dogs NOT be given Galliprant with any other NSAID or corticosteroid · Collies/MDR1 gene mutation dogs: increased risk — vet evaluation required · Serious side effects can occur without warning and in rare cases have been fatal

  The FDA’s official prescribing information for Galliprant, most recently updated in February 2025, provides the most authoritative accounting of side effects. In the original controlled field study of 285 dogs given 2 mg/kg once daily for 28 days, the most commonly observed adverse reactions were gastrointestinal: diarrhea, soft or mucoid stools, vomiting, and decreased appetite. These are the same GI side effects seen with all NSAIDs, though they tend to be milder and less frequent with Galliprant than with traditional COX inhibitors. After FDA approval, post-marketing adverse drug experience reports expanded the known side-effect profile. The AAHA (American Animal Hospital Association) reported on these FDA label changes, noting the addition of warnings about GI side effects with or without blood, anorexia, lethargy, weight loss, panting, hyperactivity, renal and hepatic bloodwork abnormalities, and ataxia. The FDA also updated the label to strengthen the warning that Galliprant must not be administered with any other oral or injectable NSAID or corticosteroid, and that concurrent use with nephrotoxic or protein-bound drugs requires caution. Dogs with the ABCB1-1Δ (MDR1) gene mutation — common in collies, Australian shepherds, shelties, and related herding breeds — may have impaired ability to metabolize Galliprant, increasing drug levels and potential toxicity. Baseline bloodwork and urinalysis are required before starting Galliprant; ongoing monitoring is recommended for long-term use, though some vets find annual monitoring adequate for stable patients on Galliprant (compared to more frequent monitoring typically needed for traditional NSAIDs).
• 6
  How much does Galliprant cost compared to meloxicam and carprofen? Galliprant: approximately $2.00–$3.50 per dose · Generic carprofen: $0.30–$0.80 per dose · Meloxicam (generic): comparable to carprofen · For a 60-lb dog: Galliprant ≈ $60–$100/month vs. generic carprofen ≈ $10–$25/month · Galliprant is approximately 4–8× more expensive than generic carprofen · Galliprant is not eligible for most discount card programs (e.g., WiseRX) — generics like carprofen and Previcox often are

  Cost is the single most common practical barrier to Galliprant use, and it is substantial. Bestie Paws Hospital’s December 2025 analysis puts Galliprant’s per-dose cost at $2.00–$3.50, while generic carprofen runs $0.30–$0.80 per dose — a difference of approximately 4 to 8 times. For a medium-to-large dog requiring daily long-term treatment, this translates to $60–$100 per month for Galliprant versus $10–$25 per month for generic carprofen. Meloxicam in generic form (available under several brand names including Metacam and generics) is similarly priced to generic carprofen. The cost gap has real-world consequences: the “best” medication is only the best if it can be administered consistently every single day. Galliprant has a 4.7-hour plasma half-life, meaning that blood levels reach their minimum therapeutic point at the 24-hour mark. Extending doses to every 48 hours — a common cost-saving modification owners attempt without veterinary guidance — effectively creates a drug holiday where pain control is lost for 12–18 hours of every cycle. For dogs who cannot afford consistent daily Galliprant dosing, a combination of generic carprofen with a GI-protective agent (like famotidine) can approach similar total monthly cost while providing more consistent pain control than intermittent Galliprant. Always discuss cost realities openly with your veterinarian — there is no shame in it, and most vets have practical alternatives ready. Note: Galliprant is currently not eligible for common pet prescription discount cards; other drugs like Previcox (firocoxib) and generic carprofen often qualify for meaningful discounts.
• 7
  What is Librela, and how does it compare to Galliprant? Librela (bedinvetmab) = FDA-approved monthly injectable monoclonal antibody for canine OA pain · Works by neutralizing nerve growth factor (NGF) — completely different mechanism from all NSAIDs · Does NOT inhibit COX enzymes or EP4 receptor · Safer for dogs with kidney or liver disease where even Galliprant carries risk · Given by injection at the vet clinic once monthly · Galliprant: daily oral tablet; Librela: monthly injection — different compliance profiles · May be used together with Galliprant under veterinary supervision

  Librela (bedinvetmab) represents the most significant advance in canine arthritis treatment in decades. Developed by Zoetis and FDA-approved specifically for dogs, it is a monoclonal antibody that neutralizes canine nerve growth factor (NGF) — a protein that plays a central role in pain signaling in osteoarthritis. By preventing NGF from binding to its receptors, Librela interrupts the pain signal at a completely different point in the cascade than any NSAID or EP4 blocker. Because Librela does not touch COX enzymes, prostaglandin production, or the EP4 receptor, it carries essentially none of the GI, renal, or hepatic risks of NSAID-class medications. This makes it particularly important for dogs with kidney disease, liver disease, or severe GI histories where even Galliprant may be too risky for long-term use. The monthly injection format provides consistent blood levels without owner compliance uncertainty — a meaningful advantage over daily oral medications, which are frequently missed or irregularly given. The tradeoff is that it requires a monthly clinic visit and the cost is typically $80–$160 per month depending on the dog’s weight and geographic market. Galliprant and Librela target different pain pathways and can in some cases be used together under veterinary supervision as a synergistic multimodal pain strategy. For dogs whose pain is inadequately controlled on either drug alone, the combination may provide more complete relief than either medication individually. Always discuss with your veterinarian whether Librela is available at your clinic and appropriate for your dog’s specific condition.
• 8
  Has Galliprant ever killed a dog? — “Galliprant killed my dog” This is one of the most searched questions about this medication — and deserves a direct, honest answer. Yes — the FDA’s prescribing label for Galliprant explicitly states: “Serious side effects associated with this drug can occur with or without warning and, in some cases, result in death.” This is standard language for all veterinary NSAIDs, including carprofen and meloxicam. It does not mean the drug is uniquely dangerous — it means serious adverse events are possible in any individual dog. Risk factors include pre-existing kidney or liver disease, concurrent corticosteroid or NSAID use, dehydration, and the MDR1 gene mutation in herding breeds.

  The search query “Galliprant killed my dog” reflects something real and painful — pet owners who lost a dog while the animal was receiving this medication. It is important to address this honestly rather than dismissing it. The FDA’s official Galliprant prescribing information (updated February 2025 via animaldrugsatfda.fda.gov) contains this exact language: “Serious side effects associated with this drug can occur with or without warning and, in some cases, result in death.” Crucially, this same warning appears on the prescribing information for carprofen (Rimadyl), meloxicam (Metacam), and virtually every other veterinary NSAID. It is not evidence that Galliprant is uniquely lethal — it is the standard FDA disclosure required for all medications where serious adverse events have been reported in post-marketing surveillance. Veterinary NSAIDs as a class carry real risks for individual dogs, particularly those with undiagnosed organ disease, concurrent dehydration (which dramatically increases kidney stress from any NSAID), or simultaneous use of corticosteroids or other protein-bound drugs. The AAHA-reported label updates confirm that post-approval surveillance did identify cases of renal and hepatic bloodwork abnormalities among Galliprant-treated dogs. What this means practically: the risk is real but manageable with proper veterinary oversight. Pre-treatment bloodwork to identify kidney and liver disease, avoidance of corticosteroid combinations, adequate hydration, and regular monitoring visits are the risk-mitigation tools that keep most dogs on Galliprant safely for years. If your dog experiences any sudden change — loss of appetite, vomiting, extreme lethargy, blood in stools — stop the medication and contact your vet immediately.
• 9
  What is the correct Galliprant dosage for dogs? FDA-approved dose: 2 mg/kg (approximately 0.9 mg/lb) orally once daily · Tablets: 20 mg, 60 mg, 100 mg · Dosing: round to nearest half-tablet · With or without food (give with food if GI upset occurs) · Minimum eligibility: ≥ 9 months of age AND ≥ 8 lbs (3.6 kg) · Do NOT use in cats · Do NOT double-dose if a dose is missed · Maximum dose: use lowest effective dose for adequate pain control · Collie/MDR1 breed dogs: consult vet — increased risk of drug accumulation

  Galliprant is manufactured by Elanco Animal Health and is available in three tablet strengths: 20 mg, 60 mg, and 100 mg. The FDA-approved dosing protocol established in the registration studies is 2 mg/kg of body weight (approximately 0.9 mg/lb) given orally once every 24 hours. Doses may be calculated to the nearest half-tablet. The FDA label specifies that Galliprant should be used at the lowest dose providing adequate pain control — there is no clinical evidence that exceeding 2 mg/kg provides additional benefit, and higher doses increase side-effect risk without demonstrated advantage. Galliprant is approved only for dogs 9 months of age or older and weighing at least 8 pounds (3.6 kg); its safety has not been studied in dogs younger than 9 months, smaller than 8 lbs, pregnant or lactating, used for breeding, or with cardiac disease. It is not approved for cats and should not be given to cats. If a dose is missed, give it as soon as remembered — unless the next scheduled dose is imminent, in which case skip the missed dose entirely. Never give two doses simultaneously to compensate for a missed dose. Dogs who are members of herding breeds (collies, Australian shepherds, shelties, border collies, white German shepherds) should be tested for the MDR1/ABCB1-1Δ gene mutation before starting Galliprant, as homozygous dogs have impaired drug clearance and are at elevated risk of adverse effects at standard doses.
• 10
  Which dog arthritis medication is right for my dog — how do I choose? Senior dog, mild-moderate OA, sensitive stomach, or mild kidney/liver disease: Galliprant is often the first choice · Healthy younger/middle-aged dog needing acute or post-surgical pain relief: carprofen (Rimadyl) or meloxicam often faster and more cost-effective · Moderate-to-severe OA where one drug alone is insufficient: Galliprant + gabapentin combination · Advanced OA with significant organ disease: Librela (monoclonal antibody) avoids all NSAID risks · Dog who failed one traditional NSAID: often responds to Galliprant due to different mechanism · Budget is a significant constraint: generic carprofen or meloxicam + GI protectant (famotidine) · Never make this decision without your veterinarian — baseline bloodwork is required before any NSAID

  The honest answer is that no single medication is right for every dog, and the clinical research confirms this: study after study shows equivalent efficacy between Galliprant and traditional NSAIDs for osteoarthritis pain — meaning the decision comes down to safety profile, organ health, cost sustainability, and individual dog response. Galliprant is genuinely the best choice for dogs with prior GI intolerance to NSAIDs, early kidney or liver concerns, or those who need years of continuous daily management. It is not a better analgesic for acute post-surgical pain — carprofen and meloxicam typically work faster and more powerfully for that indication. For dogs where even Galliprant’s safety margin is insufficient — severely compromised kidneys or liver — Librela represents a genuine breakthrough that bypasses the NSAID pathway entirely. For dogs with mixed inflammatory and neuropathic pain, the Galliprant-gabapentin combination addresses both pathways simultaneously. The most important step is having a thorough conversation with your veterinarian that covers: your dog’s complete bloodwork values, the severity and type of their arthritis, your realistic monthly budget for medication, and the practical logistics of daily oral medication vs. monthly injection. Inform your vet of every supplement your dog currently takes — fish oil, joint supplements, turmeric, and herbal products can all interact with pain medications in ways that affect safety and efficacy.

Sources: FDA Animal Drug Safety Labeling (fda.gov/animal-veterinary; Galliprant label Feb 2025; concomitant NSAID/steroid prohibition; death warning; pre-treatment bloodwork requirement; animaldrugsatfda.fda.gov/adafda); DailyMed NIH (dailymed.nlm.nih.gov — grapiprant full prescribing info; 285-dog field study; MDR1 risk); Cassemiche et al. 2024 JVIM / PMC11256200 (48-dog RCT grapiprant vs meloxicam TPLO; no statistically significant difference; randomized double-blind); AAHA Trends Magazine (aaha.org — post-approval adverse reactions added to Galliprant label; renal/hepatic abnormalities; concurrent drug warning); Elanco / Galliprant (yourpetandyou.elanco.com — EP4 mechanism; FDA approval; 9 months/8 lbs eligibility; reduced kidney/liver impact); VCA Animal Hospitals (vcahospitals.com — MDR1 caution; monitoring protocol; not for cats); GoodRx Veterinary (goodrx.com/pet-health/dog — grapiprant overview; MDR1 herding breeds; dosing Aug 2025); Great Pet Care (greatpetcare.com — OA affects 20% dogs over 1 year; arthritis meds comparison; Jun 2025); Bestie Paws Hospital (bestiepaws.com — $2–$3.50/dose Galliprant; $0.30–$0.80 carprofen; 4.7-hour half-life; dose holiday risk; safety margin Dec 2024/Mar 2025); Simon Vet Surgical (simonvetsurgical.com — 7 arthritis meds; Librela; Oct 2025); Ask A Vet (askavet.com — 2025 grapiprant guide; EP4 mechanism; organ-sparing; Dec 2025); ThePetVet (thepetvet.com — Galliprant 60mg vs alternatives; carprofen $0.75–$1.50/day; Mar 2026); HardyPaw (hardypaw.com — Galliprant vs Rimadyl; $60–$100/month; Jun 2025); Dutch Vet (dutch.com — Galliprant vs Rimadyl; Rimadyl from 6 weeks age); WiseRX (wiserxcard.com — Galliprant not eligible for discount card; Previcox/Rimadyl may qualify)

Sources: Great Pet Care (Jun 2025); Elanco (yourpetandyou.elanco.com); FDA DailyMed (dailymed.nlm.nih.gov — Feb 2025 label); Cassemiche et al. 2024 (PMC11256200); Bestie Paws (Dec 2025); ThePetVet (Mar 2026); WiseRX (wiserxcard.com)

Each medication targets canine arthritis pain through a different mechanism. Understanding what each one does — and does not — treat is the foundation of choosing the right option with your veterinarian.

Sources: FDA DailyMed (dailymed.nlm.nih.gov — Galliprant label); Great Pet Care (greatpetcare.com — arthritis med comparison Jun 2025); Bestie Paws (bestiepaws.com — cost data Dec 2025); Simon Vet Surgical (simonvetsurgical.com — Librela; Oct 2025); Dutch Vet (dutch.com — Rimadyl vs Galliprant); AAHA (aaha.org — label update); GoodRx Vet (goodrx.com/pet-health/dog); Ask A Vet (askavet.com — Dec 2025)

Sources: FDA DailyMed/animaldrugsatfda.fda.gov (label warnings; death warning; GI/kidney/liver adverse events; concomitant drug prohibition); AAHA (post-approval adverse reactions; GI/renal/hepatic abnormalities; aaha.org); Bestie Paws Hospital (bestiepaws.com — cost analysis; 4.7-hr half-life; dose holiday risk; Dec 2024/Mar 2025); Ask A Vet (askavet.com — 2025 monitoring guide; Dec 2025); VCA Animal Hospitals (vcahospitals.com — MDR1 caution; washout protocol; periodic bloodwork); GoodRx (goodrx.com/pet-health/dog — MDR1 herding breeds; Aug 2025); Great Pet Care (greatpetcare.com — Adequan; Librela; Jun 2025); WiseRX (wiserxcard.com — Galliprant not eligible; alternatives); Simon Vet Surgical (simonvetsurgical.com — Librela; combination therapies; Oct 2025)

Use the buttons below to find veterinary clinics near you that treat canine arthritis and prescribe medications including Galliprant. Always call ahead to confirm availability and discuss your dog’s specific needs before visiting.